To further analyze the effect of NLRP3, the same protocol was used for infection and oxLDL treatment, but MDMs were treated with a potent NLRP3 inhibitor, MCC950 (0.4 μg/mL) (see Supplementary Materials Figure S1 for experimental outline, Figure 3A–D). This evidence concerns the gene NLRP3 and infection.